文献速递瓣膜病与结构性心脏病

主动脉瓣反流的当代诊断与治疗:最新综述

Contemporary Diagnosis and Treatment of Aortic Regurgitation: A State-of-the-Art Review.
PubMed 文献 · J Am Coll Cardiol · 2025-10-28

主动脉瓣反流(AR)呈进行性且常被低估,未及时干预可致左室重构和心衰。尽管有I类指南指征,许多患者(尤其高龄、衰弱、多病共存者)仍未获治疗。高保真多模态影像(心脏磁共振、四维血流、斑点追踪超声)可更早检出重构并更准确量化反流负荷,可能重新定义治疗阈值并促成生物标志物-影像复合分期。外科手术仍是原生AR金标准,术式按年龄、解剖和根部病变个体化;经导管主动脉瓣置换(TAVR)在禁忌/高危患者中快速扩展,但为钙化性狭窄设计的器械在原生AR面临技术障碍,专用AR系统已在欧洲获批、美国授权可期。本综述汇总病理生理、诊断进展及外科与经导管技术创新,指出知识缺口并提出研究优先方向。

要点

  • AR进行性且常被低估,未及时干预可致左室重构和心衰。
  • 多模态影像(CMR、四维血流、斑点追踪超声)助早期检出重构和精准量化反流。
  • 外科仍为原生AR金标准;TAVR在高危/禁忌患者中扩展,专用AR器械前景可期。

核心结论

  • AR常被低估且治疗不足,影像进步与外科及经导管技术创新有望缩小治疗差距。

研究设计与样本

  • 本文为最新综述,汇总AR病理生理、诊断进展及外科与经导管治疗创新。

主要发现

  • 高保真多模态影像(心脏磁共振、四维血流、斑点追踪超声)可更早检出左室重构并更准确量化反流负荷。
  • 为钙化性狭窄设计的TAVR器械在原生AR面临大而無钙化瓣环、椭圆根部几何和高每搏量等障碍,导致锚定欠佳、残余瓣周反流和器械栓塞。
  • 专用AR系统采用瓣叶接合锚定和增强密封,在可行性及关键研究中显示鼓舞性结果,已在欧洲获批,美国授权可期。

关键数值与推荐

  • 尽管有I类指南指征,许多AR患者(尤其高龄、衰弱、多病共存者)仍未接受治疗。
  • 外科主动脉瓣置换仍是多数候选者的主要治疗,瓣膜保留根部手术、Ross手术和主动脉瓣新瓣叶成形术在经验中心用于精选低危患者。

临床怎么用

  • 对AR患者应提高识别,结合多模态影像评估重构和反流负荷,按年龄、解剖和根部病变个体化选择外科术式。
  • 对外科禁忌或高危患者可考虑TAVR,但需注意原生AR的解剖挑战和专用器械的可及性。

局限性

  • 本文为综述,未报告原始研究数据;专用AR器械的美国授权尚待批准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aortic regurgitation (AR) is progressive and frequently under-recognized; without timely intervention it drives adverse left-ventricular remodeling and heart failure. Despite Class I guideline indications, many patients-especially older, frail individuals with multimorbidity-remain untreated. Advancements in high-fidelity multimodality imaging-including cardiac magnetic resonance, 4-dimensional flow, and speckle-tracking echocardiography-have enabled earlier detection of remodeling and more accurate quantification of regurgitant burden. These techniques are redefining thresholds for treatment and may enable biomarker-imaging composite staging of disease. Surgery remains the gold standard of therapy for native AR. Contemporary surgical management is tailored to age, anatomy, and root pathology. Although surgical aortic valve replacement remains the predominant therapy for most candidates, valve-sparing root procedures, the Ross operation, and aortic valve neocuspidization are increasingly offered at experienced centers for carefully selected lower-risk patients. Transcatheter aortic valve replacement is expanding rapidly as a viable option that helps bridge the treatment gap for those at prohibitive or high risk for surgery. Yet, devices optimized for calcific aortic stenosis encounter technical obstacles in native AR-including large, noncalcified annuli, elliptical root geometry, and high stroke volumes-leading to suboptimal anchoring, residual paravalvular regurgitation, and device embolization. Purpose-built AR systems with leaflet-engaging anchoring and enhanced sealing have shown encouraging outcomes in feasibility and pivotal studies and have obtained commercial approval in Europe, and U.S. authorization is anticipated. This state-of-the-art review synthesizes current insights into AR pathophysiology, diagnostic advances, and therapeutic innovations in surgical and transcatheter techniques, highlighting knowledge gaps and proposing research priorities to accelerate access to care for this historically undertreated population.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Pawar S, Allen C, Mori M, et al. Contemporary Diagnosis and Treatment of Aortic Regurgitation: A State-of-the-Art Review. J Am Coll Cardiol. 2025. PMID: 41194752. doi:10.1016/j.jacc.2025.10.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。